The market saw significant declines today in several companies within the health care sector, particularly among those specializing in biotechnology and pharmaceutical preparations. Organon & Co. (OGN) experienced a substantial drop of 26.91%, with its last sale recorded at $9.45. The company's market capitalization now stands at approximately $2.44 billion. Contributing to this decline is a negative revenue growth rate of -2.2% and a decline in EPS by -20.54%, indicating challenges in profitability and growth. One bright spot is the company's gross margins, whih are at 57%, aligning with the industry average.
Arvinas Inc. (ARVN) also saw a steep decline of 24.84%, with its share price at $7.23. Despite a notable revenue growth rate of 43.69%, the company is grappling with negative EPS growth of -5.4% and a net loss per share of $2.77. The negative PEG ratio and the absence of a dividend yield further highlight the financial struggles the company faces. The company's gross margins are not available, but the current ratio of 4.64 indicates a strong ability to cover short-term liabilities.
Pulmonx Corporation (LUNG) dropped by 21.95%, with shares priced at $3.77. The company, which operates in the medical/dental instruments industry, reported a revenue growth of 20.73%. However, its margins remain negative, with a 69% drop, and its net debt/EBITDA stands at 0.54, reflecting potential financial strain. The company's free cash flow declined by 54.96%, indicating difficulties in generating cash from operations.
Phathom Pharmaceuticals Inc. (PHAT) saw its shares decrease by 21.68%, closing at $3.36. Its EPS has declined by 209.94%, and the free cash flow has fallen -48.78%. Despite having a current ratio of 4.2, which suggests adequate liquidity, the company's lack of profitability point to considerable operational and financial hurdles. .
| Symbol | Name (Country) | Price | % Change | Market Cap | Industry |
|---|---|---|---|---|---|
| HPH | Highest Performances Holdings (China) | $5.83 | -48.91% | $2.18 Billion | Investment Managers |
| OGN | Organon & Co. (United States) | $9.48 | -26.91% | $2.44 Billion | Biotechnology: Pharmaceutical Preparations |
| ARVN | Arvinas (United States) | $7.18 | -24.84% | $497.22 Million | Biotechnology: Pharmaceutical Preparations |
| LUNG | Pulmonx Corporation (United States) | $3.79 | -21.95% | $150.03 Million | Medical/Dental Instruments |
| PHAT | Phathom Pharmaceuticals (United States) | $3.34 | -21.68% | $233.98 Million | Biotechnology: Pharmaceutical Preparations |
We publish yearly stock data sourced directly from the SEC database, like the manuals of investment of old. Check out (the S&P 500 version.)
